About the company
Macrocyclics, Inc., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine.
Partners:
Research
Providing tools and solutions in the field of nuclear medicine for site-specific bioconjugation, advanced chelating agent technology, and peptide intermediates.
GMP manufacturing
Macrocyclics introduced its cGMP manufacturing services in 2005. Our quality system is designed specifically for the manufacture of APIs to be used in clinical trials.
Services
Our team provides comprehensive technical support for all catalog products. We also offer custom synthesis, contract manufacturing, and project consultation tailored to specific needs.
What’s In Store?
4-Aminobutyl-DOTA
Bifunctional Chelators (BFCs)
Azido-mono-amide-DOTA
Bifunctional Chelators (BFCs)
Azido-mono-amide-DOTA-tris(t-Bu ester)
Bifunctional Chelators (BFCs)
4-Aminobutyl-DOTA-tris (t-butyl ester)
Bifunctional Chelators (BFCs)
2-Aminoethyl-mono-amide-DOTA-tris(t-Bu ester)
Bifunctional Chelators (BFCs)
DO2A
Macrocyclic Ligands
DO3A
Macrocyclic Ligands
DO3A-DBCO
Bifunctional Chelators (BFCs)
News & Events
Stay informed on new technology, partnerships, collaborations, and events.
May 30 – June 1, 2017
10th International Symposium on Targeted Alpha Therapy, TAT-10
October 21-25, 2017
EANM – European Association of Nuclear Medicine – 2017
June 23-26, 2018